Диссертация (Патофизиологическое значение ацетилхолина в пролиферации опухолевых клеток толстой кишки in vitro и in vivo), страница 22

Molecular and functional characterization of cholinetransporter in human colon carcinoma HT-29 cells // Archives of Biochemistry andBiophysics. 2009. № 1 (483). C. 90–98.108. Lanza G. [et al.]. Colorectal tumors: The histology report // Digestive and LiverDisease. 2011. (43). C. S344–S355.109. Lappano R., Maggiolini M. GPCRs and cancer // Acta Pharmacologica Sinica.2012. № 3 (33). C.

351–362.110. Lee C.-H., Wu C.-H., Ho Y.-S. From Smoking to Cancers: Novel Targets toNeuronal Nicotinic Acetylcholine Receptors // Journal of Oncology. 2011. (2011).C. 1–10.111. Leu R. Le The colonic response to genotoxic carcinogens in the rat: regulationby dietary fibre 2002. № 7 (23). C.

1131–1137.112. Lindqvist S.M. [et al.]. Acetylcholine-lnduced calcium signaling along the ratcolonic crypt axis // Gastroenterology. 1998. № 5 (115). C. 1131–1143.113. Lloyd R. V [et al.]. Prevalence and Prognostic Significance of NeuroendocrineDifferentiation in Colorectal Carcinomas // Endocr Pathol. 1998. № 1 (9). C. 35–42.114. López-Otín C., Matrisian L.M. Emerging roles of proteases in tumour139suppression. // Nature reviews. Cancer.

2007. № 10 (7). C. 800–808.115. Marisa L. [et al.]. Gene Expression Classification of Colon Cancer intoMolecular Subtypes: Characterization, Validation, and Prognostic Value // PLoSMedicine. 2013. № 5 (10).116. Martinez-Lopez de Castro A. [et al.]. Cancer-associated differences inacetylcholinesterase activity in bronchial aspirates from patients with lung cancer //Clin Sci (Lond). 2008. № 8 (115).

C. 245–253.117. Mazhar D. COX and cancer // Qjm. 2005. № 10 (98). C. 711–718.118. Medjber K. [et al.]. Lung Cancer Role of nicotinic acetylcholine receptors incell proliferation and tumour invasion in broncho-pulmonary carcinomas // LungCancer. 2015. № 3 (87). C. 258–264.119. Medzhitov R. Origin and physiological roles of inflammation. // Nature. 2008.№ 7203 (454). C. 428–435.120.

Meregnani J. [et al.]. Anti-inflammatory effect of vagus nerve stimulation in arat model of inflammatory bowel disease // Autonomic Neuroscience. 2011. № 1–2(160). C. 82–89.121. Messick C. a. [et al.]. Serrated polyps: new classifications highlight clinicalimportance // Colorectal Disease. 2012. № 11 (14). C. 1328–1337.122. Miller E. Химический канцерогенез 1956.123. Montuschi P. [et al.]. Pharmacological treatment of chronic obstructivepulmonary disease: from evidence-based medicine to phenotyping // DrugDiscovery Today.

2014. № 0 (0). C. 1–8.124. Moolgavkar S.H., Knudson a G. Mutation and cancer: a model for humancarcinogenesis. // Journal of the National Cancer Institute. 1981. № 6 (66). C. 1037–1052.125. Morgan D.M. Tetrazolium (MTT) assay for cellular viability and activity. //Methods in molecular biology (Clifton, N.J.). 1998. № 4 (79). C. 179–183.126. Morikawa T. [et al.]. Tumor TP53 expression status, body mass index andprognosis in colorectal cancer // International Journal of Cancer.

2012. № 5 (131).C. 1169–1178.140127. Mosmann T. Rapid colorimetric assay for cellular growth and survival:application to proliferation and cytotoxicity assays. // Journal of immunologicalmethods. 1983. № 1–2 (65). C. 55–63.128. Noonan D.M. [et al.]. Inflammation, inflammatory cells and angiogenesis:decisions and indecisions // Cancer and Metastasis Reviews. 2008. № 1 (27). C.

31–40.129. Novotny A. Aspects of Non-Neuronal Signalling Functions of Acetylcholine inColorectal Cancer Aspects of Non-Neuronal Signalling Functions of Acetylcholinein Colorectal Cancer / A. Novotny, 2009.130. Novotny A. [et al.]. A pharmacological analysis of the cholinergic regulation ofurokinase-type plasminogen activator secretion in the human colon cancer cell line,HT-29 // European Journal of Pharmacology.

2010. № 1–3 (646). C. 22–30.131. Novotny A. [et al.]. Is acetylcholine a signaling molecule for human coloncancer progression? // Scandinavian Journal of Gastroenterology. 2011. № 4 (46). C.446–455.132. Okabe S., Roth J.L. a., Pfeiffer C.J. A method for experimental, penetratinggastric and duodenal ulcers in rats // The American Journal of Digestive Diseases.1971. № 3 (16). C.

277–284.133. Owczarek D. [et al.]. Biological therapy of inflammatory bowel disease. //Polskie Archiwum Medycyny Wewnętrznej. 2009. № 1–2 (119). C. 84–8.134. Peddareddigari V.G., Wang D., Dubois R.N. The tumor microenvironment incolorectal carcinogenesis // Cancer Microenvironment. 2010. № 1 (3). C. 149–166.135. Pelissier-Rota M. [et al.]. Role of Cholinergic Receptors in Colorectal Cancer:Potential Therapeutic Implications of Vagus Nerve Stimulation ? 2013. № August(2013).

C. 1116–1131.136. Peng Z. [et al.]. Cholinergic muscarinic receptor activation augments murineintestinal epithelial cell proliferation and tumorigenesis. // BMC cancer. 2013. (13).C. 204.137. Perše M., Cerar A. Morphological and molecular alterations in 1,2dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats //141Journal of Biomedicine and Biotechnology. 2011. (2011). C. 1–14.138. Petko Z. [et al.]. Aberrantly Methylated CDKN2A , MGMT , and MLH1 inColon Polyps and in Fecal DNA from Patients with Colorectal Polyps // ClinicalCancer Research.

2005. (11). C. 1203–1209.139. Pettersson A. [et al.]. Is acetylcholine an autocrine/paracrine growth factor viathe nicotinic α7-receptor subtype in the human colon cancer cell line HT-29? //European Journal of Pharmacology. 2009. № 1–3 (609). C. 27–33.140. Phipps I.

[et al.]. KRAS-mutation status in relation to colorectal cancersurvival: the joint impact of correlated tumour markers. // British journal of cancer.2013. № 8 (108). C. 1757–64.141. Pino M.S., Chung D.C. The Chromosomal Instability Pathway in Colon Cancer// Gastroenterology. 2010. № 6 (138).

C. 2059–2072.142. Potaros T. [et al.]. Evidence for the involvement of adenomatous polyposis coli(APC) protein in maintaining cellular distributions of α3β4 nicotinic receptors //Neuroscience Letters. 2011. № 2 (489). C. 105–109.143. Putoczki T.L. [et al.]. Interleukin-11 Is the Dominant IL-6 Family Cytokineduring Gastrointestinal Tumorigenesis and Can Be Targeted Therapeutically //Cancer Cell. 2013. № 2 (24). C. 257–271.144.

Rad R. [et al.]. A Genetic Progression Model of BrafV600E-Induced IntestinalTumorigenesis Reveals Targets for Therapeutic Intervention // Cancer Cell. 2013.№ 1 (24). C. 15–29.145. Raju J. Azoxymethane-induced rat aberrant crypt foci: Relevance in studyingchemoprevention of colon cancer // World Journal of Gastroenterology. 2008.

№ 43(14). C. 6632–6635.146. Raufman J.-P. [et al.]. Muscarinic receptor agonists stimulate matrixmetalloproteinase 1-dependent invasion of human colon cancer cells // Biochemicaland Biophysical Research Communications. 2011. № 2 (415). C. 319–324.147. Raufman J.-P., Cheng K., Zimniak P. Activation of muscarinic receptorsignaling by bile acids: physiological and medical implications.

// Digestive diseasesand sciences. 2003. № 8 (48). C. 1431–44.142148. Reddy B.S. [et al.]. Colon carcinogenesis with azoxymethane anddimethylhydrazine in germ-free rats. // Cancer research. 1975. № 2 (35). C. 287–90.149. Reddy B.S. [et al.]. Prevention of Azoxymethane-Induced Colon Cancer byCombination of Low Doses of Atorvastatin, Aspirin, and Celecoxib in F 344 Rats //Cancer Research. 2006. № 8 (68).

C. 4542–4547.150. Reddy B.S., States U. Dietary Fat and Colon Cancer: Animal Model Studies 11992. № 10 (27). C. 807–813.151. Rizzo A. [et al.]. Intestinal inflammation and colorectal cancer: a double-edgedsword? // World journal of gastroenterology : WJG. 2011. № 26 (17). C. 3092–100.152. Roca F. [et al.]. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9),and TIMPs (1 and 2) in patients with colorectal carcinoma // Journal of SurgicalOncology. 2006. № 2 (93). C.

151–160.153. Rodrigues N.R. [et al.]. P53 Mutations in Colorectal Cancer. // Proceedings ofthe National Academy of Sciences of the United States of America. 1990. № 19(87). C. 7555–9.154. Roeb E. Matrix metalloproteinase-13 is regulated by toll-like receptor-9 incolorectal cancer cells and mediates cellular migration // Oncology Letters. 2011.

C.483–488.155. Rosenberg D.W. [et al.]. Mouse models for the study of colon carcinogenesis //Carcinogenesis. 2009. № 2 (30). C. 183–196.156. Rosenvinge E.C. von [et al.]. Bedside to Bench: Role of Muscarinic ReceptorActivation in Ultrarapid Growth of Colorectal Cancer in a Patient WithPheochromocytoma // Mayo Clinic Proceedings.